A phase 1, randomized, double-blind, single-center, placebo-controlled study to evaluate the safety, tolerability and pharmacokinetics of ascending single oral doses of XW10172 in healthy adult subjects
Phase of Trial: Phase I
Latest Information Update: 08 Jun 2018
At a glance
- Drugs XW-10172 (Primary)
- Indications Neurological disorders
- Focus Adverse reactions; First in man
- Sponsors XW labs
- 06 Jun 2018 Planned End Date changed from 22 Jun 2018 to 2 Aug 2018.
- 06 Jun 2018 Status changed from not yet recruiting to recruiting.
- 01 Feb 2018 New trial record